Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Roche Holding AG

Market Cap 261B 330B 284B 246B 462B 31,098B 466B 3,097B 1,206B 15,262B 1,237B 1,210B 52,799B P/E 2026 *
17.5x
P/E 2027 * 16.3x
Enterprise Value 272B 343B 296B 256B 481B 32,339B 485B 3,221B 1,254B 15,872B 1,286B 1,259B 54,907B EV / Sales 2026 *
4.34x
EV / Sales 2027 * 4.08x
Free-Float
88.78%
Yield 2026 *
3.05%
Yield 2027 * 3.13%
1 day-1.73%
Current month+0.08%
6 months+0.99%
Current year-1.68%
Current year 311.6
Extreme 311.6
377
1 year 221.3
Extreme 221.3
377
3 years 212.3
Extreme 212.3
377
5 years 212.3
Extreme 212.3
404.1
10 years 202.23
Extreme 202.231
404.1
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Operating Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 68 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
-1.68%0.00% - - 330B
-1.31%-5.56%+39.66%+142.59% 992B
-2.47%-3.81%+52.10%+39.68% 564B
-2.26%-3.29%+17.19%+57.72% 391B
-2.17%-2.92%+24.97%+13.19% 280B
-2.09%-2.52%+24.76%+30.41% 279B
-1.91%-1.08%-42.07%-48.37% 196B
-1.79%-4.85%+16.32%+47.38% 184B
-2.06%-2.05%+14.15%+58.65% 156B
-3.49%-4.20%+4.98%-36.27% 148B
Average -2.12%+0.30%+16.90%+33.89% 354.38B
Weighted average by Cap. -1.95%-0.70%+27.28%+63.19%

Financials

2026 *2027 *
Net sales 62.56B 78.87B 68.04B 58.88B 111B 7,443B 112B 741B 289B 3,653B 296B 290B 12,638B 65.06B 82.02B 70.76B 61.23B 115B 7,741B 116B 771B 300B 3,799B 308B 301B 13,143B
Net income 15.23B 19.2B 16.56B 14.33B 26.93B 1,812B 27.15B 180B 70.24B 889B 72.05B 70.51B 3,076B 16.24B 20.48B 17.67B 15.29B 28.73B 1,933B 28.97B 193B 74.95B 949B 76.87B 75.23B 3,282B
Net Debt 10.43B 13.15B 11.35B 9.82B 18.45B 1,241B 18.61B 124B 48.14B 609B 49.37B 48.32B 2,108B 3.76B 4.74B 4.09B 3.54B 6.64B 447B 6.7B 44.51B 17.33B 219B 17.77B 17.39B 759B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
18/06/26 322.61 CHF -0.40% 182
17/06/26 323.90 CHF 0.00% 289,037
16/06/26 323.90 CHF 0.00% 184,548
15/06/26 323.90 CHF 0.00% 236,877
12/06/26 323.90 CHF 0.00% 194,314
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
327.80CHF
Average target price
358.83CHF
Spread / Average Target
+9.47%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!